Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 3219

Similar articles for PubMed (Select 15130461)

1.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

Clark W, Jobanputra P, Barton P, Burls A.

Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. Review.

2.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

3.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

4.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

5.

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.

Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2006 Dec;10(49):iii-iv, ix-xi, 1-157. Review.

6.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

7.
8.
9.

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.

Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A.

Mod Rheumatol. 2006;16(2):77-84.

PMID:
16633926
10.

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA.

Drugs. 2005;65(4):473-96. Review.

PMID:
15733011
11.

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.

12.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

13.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

14.

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Lyseng-Williamson KA, Foster RH.

Pharmacoeconomics. 2004;22(2):107-32. Review.

PMID:
14731052
15.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

16.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

17.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

18.

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.

Kielhorn A, Porter D, Diamantopoulos A, Lewis G.

Curr Med Res Opin. 2008 Sep;24(9):2639-50. doi: 10.1185/03007990802321683 . Epub 2008 Aug 6.

PMID:
18687164
19.

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

Rheumatology (Oxford). 2007 Nov;46(11):1729-35.

20.

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P; 20000223 Study Group.

Arthritis Rheum. 2004 May;50(5):1412-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk